Brokerages Set The Cooper Companies, Inc. (NASDAQ:COO) PT at $117.00

The Cooper Companies, Inc. (NASDAQ:COO) has been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $117.00.

COO has been the subject of a number of recent research reports. Morgan Stanley cut their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Friday, December 6th. Citigroup dropped their price target on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, December 6th. StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a report on Friday, December 6th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $115.00 price target (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th.

Cooper Companies Price Performance

Shares of COO opened at $94.49 on Friday. Cooper Companies has a twelve month low of $84.76 and a twelve month high of $112.38. The company has a market capitalization of $18.86 billion, a P/E ratio of 48.46, a price-to-earnings-growth ratio of 2.52 and a beta of 0.97. The firm has a 50 day moving average of $103.04 and a 200 day moving average of $99.00. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.03 billion. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.87 EPS. As a group, equities research analysts anticipate that Cooper Companies will post 3.98 earnings per share for the current fiscal year.

Insider Buying and Selling at Cooper Companies

In other news, CEO Albert G. White III sold 114,992 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total value of $12,710,065.76. Following the sale, the chief executive officer now directly owns 165,273 shares in the company, valued at approximately $18,267,624.69. This represents a 41.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Cooper Companies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Innealta Capital LLC purchased a new position in Cooper Companies during the 2nd quarter valued at about $25,000. Ashton Thomas Securities LLC purchased a new position in shares of Cooper Companies during the 3rd quarter valued at about $25,000. Crewe Advisors LLC lifted its holdings in Cooper Companies by 286.4% in the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 252 shares during the period. Tortoise Investment Management LLC lifted its stake in shares of Cooper Companies by 75.4% in the 2nd quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 169 shares during the period. Finally, Covestor Ltd raised its position in shares of Cooper Companies by 144.9% in the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after acquiring an additional 200 shares during the period. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.